With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, Board ....

Revenue declinedNet loss reportedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹26.40

prior close

₹26.16

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-1.2% vs market

Pharmaceuticals peers, median of 165sector-0.1%-1.0% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.2

15m

-0.2

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+0.1-1.2-0.1-1.0

Next day

-0.6+1.7-2.2+0.9-1.5

+6.1+2.4+3.7+0.9+5.2

+24.6+2.4+22.3+0.7+23.9

+8.0+1.7+6.2+0.8+7.1

+14.8+0.6+14.2+0.0+14.8

+10.3+1.9+8.4-0.0+10.4

15d

+3.5+4.9-1.4+1.1+2.4

+5.1+8.9-3.8+3.0+2.1

-3.4+7.5-10.9+4.5-7.9

—+13.6—+7.9—

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Medi-Caps Limited's Board approved audited standalone and consolidated financial results for Q4 and FY 2025-26. Standalone revenue declined marginally to ₹230.59 Lacs from ₹241.66 Lacs, with the company reporting a net loss of ₹-13.87 Lacs versus a profit of ₹55.51 Lacs in FY 2024-25, attributed to volatile real estate market conditions. Consolidated revenue stood at ₹1244.85 Lacs but the group incurred a much larger net loss of ₹-303.75 Lacs due to unstable political conditions in its major US market. The Board also re-appointed Praveen Shrivastava & Company as internal auditor for FY 2026-27. Auditors Rawka & Associates gave an unmodified (clean) opinion on both standalone and consolidated results.

Likely market impact

The sharp swing to losses on both standalone and consolidated basis, coupled with mentions of volatile real estate conditions and unstable political conditions in the US, signals deteriorating financial health and could weigh on investor sentiment near-term.